Clinical Trial Update: An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease [Phase 2]

View source ↗

Summary

Open-label, multicenter Phase 2 study of Brincidofovir for Ebola virus disease has been withdrawn from further investigation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• Brincidofovir (brincidofovir)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Ebola Virus | Phase 2 | Status: WITHDRAWN